GlycoNex

GlycoNex Interest Coverage

The Interest Coverage Ratio of GlycoNex (4168.TWO) as of Nov 5, 2026 is -42.06. In the previous year, Interest Coverage Ratio was -50.92 — a change of -17.41% (higher).

Interest Coverage

-42.06

YoY

-17.41%

Last updated:

Interest Coverage Ratio of GlycoNex is 2024 -42.06 . Interest Coverage Ratio of GlycoNex was 2023 -50.92 . It decreases by -17.41% higher compared to the previous year.

The GlycoNex Interest Coverage history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Interest Coverage
Date
Interest Coverage
Jan 1, 2017
-24.63 TWD
Jan 1, 2018
-85.62 TWD
Jan 1, 2019
-398.03 TWD
Jan 1, 2020
-4.67 TWD
Jan 1, 2021
-103.41 TWD
Jan 1, 2022
-867.57 TWD
Jan 1, 2023
-50.92 TWD
Jan 1, 2024
-42.06 TWD
The GlycoNex Interest Coverage history
YEARInterest CoverageYoY
-42.06-17.41%
-50.92-94.13%
-867.57+738.94%
-103.41+2,112.63%
-4.67-98.83%
-398.03+364.89%
-85.62+247.59%
-24.63+67.62%
-14.69+57.35%
-9.34+241.75%
-2.73—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

GlycoNex Stock analysis

What does GlycoNex do? GlycoNex, Inc. develops anti-cancer monoclonal antibodies and bio-similar drugs, offering licensing for monoclonal antibody targets and carbohydrate antigen and protein drug services. The company targets domestic and Asian markets, distributing its products through these regions. Revenue comes from drug development, licensing agreements, and service provision for antibody targets and related biotech solutions. GlycoNex focuses on anti-cancer monoclonal antibody new drugs and bio-similar drugs, with services including carbohydrate antigen and protein drug related offerings. The firm serves domestic and overseas markets in Asia, generating income from product development, licensing, and specialized biotech services. Its business model relies on developing and commercializing innovative cancer treatments and related services in key Asian markets. The company's revenue streams include the development of anti-cancer monoclonal antibody new drugs, bio-similar drugs, and the licensing of monoclonal antibody targets. Services related to carbohydrate antigen and protein drug solutions are also part of the business, distributed across domestic and Asian markets to generate income from pharmaceutical innovation and biotech service contracts. GlycoNex is one of the most popular companies on Eulerpool.

Frequently Asked Questions about GlycoNex stock

Interest Coverage Ratio of GlycoNex is -42.06 in 2024.

Interest Coverage Ratio of GlycoNex changed from -50.92 to -42.06, representing a -17.41% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Interest Coverage Ratio GlycoNex since 2006 – with annual values, charts, and detailed analysis.

The Interest Coverage ratio measures a company's ability to pay interest on its debt. Higher ratios indicate greater financial strength and lower default risk.

Interest Coverage = EBIT / Interest Expense

A 'good' varies by industry and company stage. On Eulerpool, you can compare Interest Coverage Ratio's GlycoNex with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — GlycoNex

All Key Metrics — GlycoNex